CliffBio
small molecule

VANCOMYCIN

VANCOMYCIN

Loss of exclusivityNovember 2035latest FDA-listed patent expiry
CompanyHikma →View the full company profile on CliffBio

Drug detail

Brand nameVANCOMYCIN
Active ingredientVANCOMYCIN
Strength5GM/100ML (50MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS, ORAL
ModalitySmall molecule
FDA approvalAugust 2021
Marketing statusDISCN

Listed patents

PatentExpiresType
11517609November 2035use U-282
10188697November 2035product
10039804November 2035product
10849956November 2035product
11000567November 2035product

More from Hikma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VANCOMYCIN patent cliff — loss of exclusivity November 2035 | CliffBio